Homepage

Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT NASDAQ Categories PDF
Healthcare · Biotechnology
University Park, FL 34201, United States IPO 2026 lakewoodamedex.com Updated Jun 27, 10:07am
Price
$3.51
Market Cap
$1.6M
Employees
5
Beta
0.00
Avg Volume
273,202
CEO
Kelvin Cooper
Business Description

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

Business History
Price Overview
Last updated: Jun 27, 2026 10:07am (just now)
$3.51
+0.08 (+2.33%)
Day Range
$3.35 – $3.80
52-Week Range
$0.37 – $9.26
50-Day MA
$8.00
200-Day MA
$8.00
Volume
356,757.00
Share Structure
Outstanding 468,918.00
Float
Free Float 0.0%
Very low free float — 0.0% of shares trade freely, ~100% held by insiders/institutions
Thinly traded — expect wider bid-ask spreads and sharp price swings on modest volume. Institutional investors may avoid due to liquidity constraints.
Price History (1 Year)
Last updated: Jun 27, 2026 10:07am (just now)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Jun 27, 2026 10:07am (just now)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for LABT — it's generated by the pipeline (market-narrative step).
Community AI Feedback
No community reviews yet for LABT. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30